Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

导出原文传递

翻译打印收藏纠错

第一作者： Yasir Y,Elamin

第一单位： Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Yasir Y,Elamin ^[1] ; Daniel R,Gomez ^[2] ; Mara B,Antonoff ^[3] ; Jacqulyne P,Robichaux ^[1] ; Hai,Tran ^[1] ; Melissa K,Shorter ^[1] ; Jadi M,Bohac ^[1] ; Marcelo Vailati,Negrao ^[1] ; Xiuning,Le ^[1] ; Waree,Rinsurogkawong ^[4] ; Jeff,Lewis ^[4] ; Lara,Lacerda ^[1] ; Emily B,Roarty ^[1] ; Stephen G,Swisher ^[3] ; Jack A,Roth ^[3] ; Jianjun,Zhang ^[1] ; Vassiliki,Papadimitrakopoulou ^[1] ; John V,Heymach ^[5]

作者单位： Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. ^[2] Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX. ^[3] Department of Quantitative Research Computing, University of Texas MD Anderson Cancer Center, Houston, TX. ^[4] Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jheymach@mdanderson.org. ^[5]

关键词 EGFR mutant NSCLC Local ablative therapy Local consolidation therapy Residual disease Targeted therapy